Eternis Fine Chemicals Ltd. Overview
| Attribute | Detail | Source |
|---|---|---|
| Legal name | Eternis Fine Chemicals Limited (EFCL) | MCA via Zauba/Tracxn |
| Former name | Hindustan Polyamides & Fibres Limited (HPFL); rebranded Eternis in 2015 | Sustainability Report 2023-24; Yahoo Finance/Newsfile release, 4-Dec-2024 |
| Corporate Identification Number (CIN) | U17120MH1965PLC015806 (registration no. 15806, ROC Mumbai) | MCA via Zauba, Tracxn |
| Incorporation date | 25 February 1965 | MCA via Zauba, TheCompanyCheck, Bloomberg |
| Entry into aroma chemicals | 1988, through acquisition of a chemicals plant at Koregaon-Bhima, Pune. The company describes itself as "born in 1988". | eternis.com "Our Story" |
| Incorporation jurisdiction | Maharashtra, India (Companies Act) | MCA |
| Registered office / HQ | 1004 Peninsula Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013, India | eternis.com; Bloomberg |
| Company type (actual) | Unlisted public limited company, closely held by the Mariwala family. Your list says "Public company". That is correct legally (Indian "public limited" status), but the company is not listed on any exchange. | CRISIL rationales; TheCompanyCheck |
| Stock exchange / ticker | None (unlisted). The Bloomberg identifier 1512539D:IN is a private-company ID, not a trading ticker. | Bloomberg |
| ISIN / CUSIP | Not publicly disclosed. No exchange-traded security exists. | — |
| Fiscal year end | 31 March | CRISIL; MCA filings |
| Promoter holding | 94.38% promoters; 5.62% public/non-promoter (2023) | TheCompanyCheck (MCA-derived) |
| Paid-up capital | ₹12.459 lakh (₹1,245,900); authorised capital ₹45.55 crore | Tracxn (MCA-derived), Nov-2025 |
| Employees (latest) | 609 group employees in FY2024 (India 495, UK 114), before the Sharon PC acquisition | Sustainability Report 2023-24 |
| Employees (other data points) | 488 (Apr-2024, standalone); 493 (30-Sep-2024, standalone); "600+" (Dec-2024 press release); ~475 (LeadIQ, Mar-2026, likely LinkedIn-based). Sharon PC alone had 200+ staff in 2023. | TheCompanyCheck; Tracxn; Newsfile; LeadIQ; Newsfile Jul-2023 |
| Statutory auditor | Not publicly disclosed in sources reviewed. It is available in MCA AOC-4 filings. | — |
| Market capitalisation | Not applicable (unlisted). No observable valuation. | — |
| Credit rating | CRISIL A+/Stable (long-term); CRISIL A1 (short-term). Last full rationale Dec-2024; reiterated in Nov-2025. | CRISIL |
| Websites | www.eternis.com (group/India); www.eternis.co.uk (UK); www.sharonpc.com (personal care, now Eternis Personal Care) | Company |
| Last AGM | 6 June 2025 | Tracxn / TheCompanyCheck (MCA) |
The name on the request, "Eternis Fine Chemicals Ltd.", matches an active Indian legal entity exactly. The dossier profiles that entity and its consolidated group.
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Group employees, India + UK (count) | — | 609 | — |
| Standalone India employees (count) | — | 495 | 493 |
FY2023 and FY2025 group counts are not publicly disclosed. The FY2025 standalone figure is Tracxn as of 30-Sep-2024. A post-acquisition consolidated headcount including Sharon PC has not been published.
Eternis Fine Chemicals is a Mumbai-headquartered, Mariwala-family-controlled maker of aroma chemicals: the synthetic fragrance molecules that global flavour and fragrance (F&F) houses blend into perfumes, detergents, soaps and personal care products. It is part of the same promoter family as Marico Limited and positions itself as India's largest aroma-chemical exporter and a top-10 global producer. The company also describes itself as a top-5 independent aroma-ingredient company. Its customers include all four of the largest F&F houses: Givaudan, IFF, Firmenich (now dsm-firmenich) and Symrise. Manufacturing capacity is about 75,000 tonnes per year across four Maharashtra plants and Leek, UK. Through the December 2024 acquisition of Sharon Personal Care, rebranded Eternis Personal Care in July 2026, it has added a second business leg in cosmetic preservatives and functional ingredients, with a plant in Italy. Consolidated revenue is roughly ₹1,900–2,300 crore (about US$230–270 million). It is a commodity-to-specialty bridge player whose edge is scale in a few molecules, cost position, and its status as a supplier to the F&F majors.
What the company does
Eternis makes aroma chemicals. These are single-molecule, synthetic or nature-identical odorants such as coumarin, benzyl salicylate, hexyl cinnamic aldehyde, cyclamen aldehyde, phenyl ethyl alcohol, styrallyl acetate and the PTBCHA/OTBCHA cyclohexyl acetates. They are sold as building-block ingredients to fragrance compounders, who formulate them into fragrance oils for consumer goods.
The UK subsidiary at Leek adds aroma chemicals and acetate ester chemicals. Its liquid products serve lubricants, metalworking fluids, surface coatings, cosmetics, oilfield, pharma, paints, leather, explosives, paper, plastics, food and feed, inks, plasticiser replacements and textile auxiliaries (eternis.co.uk).
Since December 2024 the group also makes personal care ingredients through Eternis Personal Care (ex-Sharon Personal Care). The range covers preservative systems, multifunctional ingredients, actives, textures, wet-wipe solutions and sun-care ingredients (Personal Care Magazine / Cosmetics Business, Jul-2026).
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue type | Almost entirely product sales. Bulk and specialty chemicals are sold in drums, IBCs and containers. There is no subscription, licensing or service revenue of note. | Product pages; US import manifests show drum/FCL shipments |
| Pricing | Contract and spot pricing with large F&F houses. Raw materials are phenol- and crude-linked. Management has adopted formula-based pricing with key suppliers to reduce margin volatility. | Sustainability Report 2023-24; CRISIL |
| Customer concentration | Preferred supplier to Givaudan, IFF, Firmenich and Symrise. At the UK site, 72% of sales go to multinationals. | CRISIL (2022–2024); eternis.co.uk |
| Product concentration | Top six products make up a sizeable share of turnover. Hydrogenation-chemistry products and salicylates were about half of revenue (FY2022–23) and about one-third (per Dec-2024 rationale). | CRISIL Jul-2022, Oct-2023, Dec-2024 |
| Export orientation | About 75% of turnover is exported (CRISIL, FY2022–FY2024); the company itself states 80%. | CRISIL; company |
| Contract manufacturing | A historic co-production alliance with Firmenich for Hedione® (2005–09). The CEO has signalled an aim to be an "OEM manufacturer of choice". | eternis.com; P&F+ interview, 2024 |
Value-chain position
Eternis sits in the middle of the fragrance value chain:
Upstream: petrochemical intermediates (phenol, toluene derivatives, aldehydes, acetic acid), hydrogen (produced on-site in a captive plant) and palm-derived oleochemicals (100% RSPO mass-balance certified).
Midstream (Eternis): multi-step chemical synthesis, including hydrogenation, esterification, condensation and distillation.
Downstream customers: fragrance houses compound Eternis molecules into fragrance oils. These are then sold to FMCG brand owners (home care, personal care, fine fragrance).
With Eternis Personal Care, the group also sells directly to cosmetic formulators and brand owners. The SO.F.I.A Cosmétiques joint venture, which offers formulation and finished-product manufacturing in France, extends the group one step further downstream.
End-markets
| End-market | Exposure | Comment |
|---|---|---|
| Functional fragrance (detergents, soaps, household care) | Core | CRISIL describes this as a "relatively stable" segment that cushions product-concentration risk |
| Fine fragrance | Core | The company says its products go into many leading perfumed brands |
| Personal care / cosmetics (preservatives, actives, textures, wet wipes, sun care) | New since Dec-2024 | Via Eternis Personal Care |
| Food and feed / flavours | Emerging | FSSAI food licence granted for the Kurkumbh plant; UK food-grade approval expected mid-2025 |
| Industrial (lubricants, coatings, inks, plastics, explosives, leather, paper) | UK site | Acetate esters and liquid chemicals from Leek |
Company self-description vs. independent characterisation
Company self-description. No public annual report is available. In its Sustainability Report 2023-24, the company presents itself as a manufacturer of fragrance and personal-care ingredients and states its purpose as "Enriching Lives with Care". Its corporate "DNA" is "Eternally Agile, Forever Customer-Centric". It cites roughly US$233 million in annual sales, 65,000 tonnes of capacity and 80% export share, and calls itself a top-5 independent aroma-ingredient company.
Independent characterisation. Eternis is a mid-sized, export-led, scale-commodity aroma chemicals producer working to move up the specialty curve. Its margins have historically been modest for a specialty chemical company: operating margin of 10–15% and PAT margin of 3.4–4.9% over FY2021–FY2024 (CRISIL). That is well below listed Indian peer Privi Speciality, at roughly 22–26% EBITDA. The gap reflects the lower-margin UK business, raw-material pass-through lags, and intense competition from China and from the backward-integrated F&F majors.
The 2024–2026 strategy has four parts:
-
a France-based professional CEO;
-
the personal-care acquisition;
-
the downstream SO.F.I.A joint venture;
-
a sustainability-led premium (low-carbon product variants, TfS membership).
Together these amount to a deliberate effort to escape commodity economics. Execution is unproven in public data.
Strategy
Stated strategy themes
Drawn from the CEO interview (P&F+, 2024), the Sustainability Report 2023-24 and the 2024–2026 releases.
-
Grow the core aroma-chemicals business. Keep investing in capacity, molecules and agility. The company aims to be an OEM / contract manufacturer of choice for F&F houses.
-
Build a "second leg" in an adjacent market. The CEO flagged this in 2024; it was executed via Sharon Personal Care (Dec-2024) and the SO.F.I.A JV.
-
Sustainability as a differentiator. Goals include 67% renewable energy, LCAs on more than 80% of products, low-PCF alternatives for 90% of products by 2028, an SBTi-aligned decarbonisation plan, TfS membership, and capturing waste hydrogen as fuel.
-
Customer centricity and digitalisation. Initiatives cover a dedicated NPD team, a deep-sea shipment tracker, a CRM rollout (2025), a global SAP rollout (2025) and harmonised quality standards across sites.
-
Organisation building. The company is adding professional global leadership (CEO, CHRO, Head of Procurement, Head of HR Manufacturing) under the purpose "Enriching Lives with Care" and the DNA "Eternally Agile, Forever Customer-Centric."
Initiatives in the last 24 months (Oct-2024 to Oct-2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Acquisition of Sharon Personal Care | Dec-2024 | Entry into personal-care ingredients | Integrated; rebranded Jul-2026 |
| ECPL amalgamation | Filed Mar-2025 | Structural simplification | Completed |
| ChainCraft collaboration | Mar-2025 | Low-carbon, bio-based aroma chemicals using ChainCraft's SensiCraft® fatty acids | Development stage |
| TfS membership | 2,025 | Supply-chain sustainability audits; first Indian member | Active |
| SO.F.I.A Cosmétiques JV | 2025–26 | Integrated formulation and manufacturing in France | Announced; financials undisclosed |
| Trezzo SPC-1 plant | 2,025 | New 7,500 t/yr personal-care plant | Operational |
| Global CHRO and procurement build-out | Jun-2025 / Apr-2026 | People and procurement transformation | Ongoing |
| SAP and CRM rollout | 2,025 | Standardised operations | Planned per SR; completion not reported |
| UK food-grade approval | Expected mid-2025 | Food-grade facility in the UK (India approved) | Not confirmed |
| ISCC+ for all sites | Target 2025 | Mass-balance bio-attributed products | Leek certified; group status not confirmed |
| Eternis Personal Care rebrand | Jul-2026 | Unified global brand | Completed |
Sustainability targets (company-stated)
| Target | Deadline | Baseline |
|---|---|---|
| 30% reduction in Scope 1+2 GHG intensity | 2,030 | FY2023 |
| 90% reduction in Scope 1+2 GHG intensity; Net Zero | 2,050 | FY2023 |
| 30% reduction in Scope 3 intensity | 2,030 | 2,023 |
| Zero waste to landfill | 2,030 | — |
| 30% reduction in waste intensity | 2,030 | 2,023 |
| 2% per year reduction in freshwater intensity | Ongoing to 2030 | — |
| 90% of products with a lower-PCF alternative | 2,028 | — |
| 80% of raw-material spend assessed on ESG | 2,028 | — |
| TRIR below 0.3 (another section of the report says below 0.2) | 2,030 | — |
| EcoVadis Ethics score of 70 | 2,030 | — |
Medium-term financial targets / guidance
Not publicly disclosed. The only forward markers in the public domain are third-party:
-
CRISIL expected operating margin of about 13% over the medium term (Dec-2024).
-
CRISIL's upgrade trigger is 14–16% margin; its downgrade trigger is margin below 10%.
-
CRISIL expected debt/EBITDA of 2.5–2.7x by end-FY2026.
Products & Services
All India-made aroma products are EU REACH-registered and Kosher-certified (eternis.com). Halal certification and RSPO/ISCC+ chain-of-custody certifications are also held (Sustainability Report). Pricing is not publicly disclosed for any product.
Eternis Aroma Chemicals: India portfolio
| Product | Description / olfactive role | Capabilities and notes | Target customer | Launch / scale-up | Source |
|---|---|---|---|---|---|
| Coumarin | Sweet, hay-like, tonka note; widely used in fougère and oriental accords and in functional fragrance | Strengthened by the 2018 AIMS Impex acquisition. Eternis became India's only coumarin manufacturer, with AIMS reportedly holding ~50% of the Indian market. Base capacity was ~1,500 t before the deal. | F&F houses globally | Eternis entry pre-2018; AIMS acquired 2018 | eternis.com; Avendus; Outlook Business; CB Insights |
| PTBCHA (p-tert-butylcyclohexyl acetate) | Woody-floral, fruity; high-volume functional ingredient | Hydrogenation chemistry using the captive hydrogen plant | F&F houses | 1990s | eternis.com |
| PTBCHA Super / Hi-Cis | High-cis isomer grade with a stronger, more valued odour | Isomer-control capability | Fine and functional fragrance | 2000–04 | eternis.com |
| PTBCH (p-tert-butylcyclohexanol) | Intermediate / woody note | Hydrogenation | F&F | — | eternis.com |
| OTBCHA (o-tert-butylcyclohexyl acetate) | Fruity-woody, apple-like | Hydrogenation | F&F | 1990s | eternis.com |
| OTBCHA Super | High-performance isomer grade | Isomer control | F&F | — | eternis.com |
| Styrallyl Acetate | Green, gardenia-like floral | Shipped in volume to the US (e.g., Givaudan Fragrances Corp., Jul-2025 manifest) | F&F | 1990s | eternis.com; ImportInfo |
| Benzyl Salicylate | Faint balsamic-floral fixative; very high volume | Salicylate chemistry; along with hydrogenation, one of the two families that historically drove a large share of revenue | F&F | 2000–04 | eternis.com; CRISIL |
| Hexyl Salicylate | Green-floral, herbaceous | Salicylate chemistry | F&F | 2000–04 | eternis.com |
| Hamber | Ambery-woody (trade name) | Specialty molecule | F&F | 2005–09 | eternis.com |
| Hexyl Cinnamic Aldehyde (HCA) | Jasmine-like floral; high volume | Condensation chemistry | F&F | 2010–14 | eternis.com |
| Cyclamen Aldehyde Pure | Fresh-floral, cyclamen/lily-of-the-valley | Shipped to Mane USA (Jul-2025 manifest) | F&F | Launched 2015 | eternis.com; ImportInfo |
| Phenyl Ethyl Alcohol (PEA) | Rose-like floral; also a preservative booster in cosmetics | Plant scale-up from 2015; cross-sold into personal care as "Sharon PA" | F&F; cosmetics | 2,015 | eternis.com; SpecialChem |
| TMCH | Trade abbreviation; molecule not disclosed in sources | — | F&F | 2000–04 | eternis.com |
| Butyl cyclohexyl acetate | Fruity-woody | Listed by Bloomberg and EPCA | F&F | — | Bloomberg; EPCA |
| Hedione® (co-production) | Methyl dihydrojasmonate (Firmenich trademark); jasmine-transparent | Co-production alliance with Firmenich, 2005–09. The company notes the arrangement ended because the partner wanted extra capacity without investing. Current status not disclosed. | Firmenich | 2005–09 | eternis.com; Outlook Business |
Eternis Aroma Chemicals: UK (Leek) portfolio
| Product family | Description | Applications | Notes | Source |
|---|---|---|---|---|
| Aroma chemicals | Includes benzyl benzoate and benzyl salicylate | Perfumery and cosmetics | Leek is described as the UK's largest aroma-chemical producer | C&EN 2021; eternis.co.uk |
| Acetate ester chemicals | Liquid esters | Lubricants, metalworking fluids, coatings, paints, inks, pressroom chemicals, phthalate-plasticiser replacements, plastics, paper, leather, textiles, emulsion explosives, oilfield, pharma, food and feed, tobacco | Claims exports to almost 90 countries; ~24,000 t/yr output | eternis.co.uk |
None of the substances produced at Leek fall into PBT, vPvB or endocrine-disruptor categories (Sustainability Report).
Eternis Personal Care (ex-Sharon Personal Care) portfolio
| Product / platform | Description | Target customer | Latest update | Source |
|---|---|---|---|---|
| Sharon PA (phenethyl alcohol) | Solvent / preservative booster; globally approved; free of parabens, formaldehyde donors and isothiazolinones | Cosmetic formulators | Listing updated Jul-2026 under the Eternis Personal Care brand | SpecialChem |
| Sharon E50 (ethylhexylglycerin) | Emollient and preservative booster for broad-spectrum protection | Cosmetic formulators | Listing updated Jul-2026 | SpecialChem |
| Broad-spectrum preservative systems | Core heritage of Sharon Laboratories (founded 1977) | Personal care, wet wipes | Ongoing | Newsfile 2023; PCM 2026 |
| Active ingredients | Skincare actives | Brand owners / formulators | Ongoing | PCM 2026 |
| Textures and Texture Selector | Global tool to simplify texture formulation | Formulators | Launched mid-2026 | HPC Mag MEA, Jul-2026 |
| Wet-wipes solutions | Lotions and preservation for wipes | Wipes converters | Ongoing | CB Insights (RES Pharma deal context); PCM |
| Sun-care ingredients | Sun-care functional ingredients | Sun-care brands | Ongoing | PCM 2026 |
| Multifunctional ingredients | Multi-benefit functionals for next-generation formulations | Formulators | Ongoing | PCM 2026 |
Manufacturing for personal care is now cited as Italy, India and the UK (PCM, Jul-2026), which suggests cross-loading onto the legacy Eternis plants.
Services
Application labs: Italy and US. Sharon opened a US application lab and sales office in 2023.
Microbiology research lab: Israel.
Regulatory dossier support: REACH registrations and downstream-user safety communication.
Product carbon footprint (PCF) data: LCAs completed for more than 80–90% of products.
Low-carbon variants: Lower-PCF product alternatives, with a target that 90% of products have a lower-PCF alternative by 2028.
Turnkey beauty: End-to-end formulation-to-finished-product services via the SO.F.I.A Cosmétiques JV.
None is monetised separately in disclosed data.
Financial Narrative
Data basis. All figures are consolidated (Eternis + UK subsidiaries ± ECPL) as presented in CRISIL rationales, which are drawn from audited financials but analytically adjusted (e.g., CRISIL amortises acquisition goodwill over five years). Because there is no public annual report, the following are not publicly disclosed: gross profit, EPS, dividends per share, reported EBITDA and segment data. Blank cells mean "not publicly disclosed." FY2025 actuals have not been published by CRISIL in sources reviewed; the FY2025 revenue shown is CRISIL's December-2024 projection, corroborated by Tracxn's MCA-derived ₹2,300 crore figure.
Income statement
Sources: CRISIL rationales of 6-Jul-2022 (FY2021, FY2022 margin), 4-Oct-2023 (FY2022 restated income, FY2023), 13-Dec-2024 (FY2024; FY2025 projection ~₹2,300 crore). FY2022 income is ₹1,895 crore in the Jul-2022 rationale versus ₹1,902 crore in Oct-2023; the latter is used. The FY2022 growth figure (76%) is CRISIL's own. EBITDA is derived.
Revenue CAGR (derived): FY2021→FY2024 ≈ 21% (₹1,079 → ₹1,911 crore), mainly inorganic from Tennants. FY2022→FY2024 ≈ 0%, reflecting flat organic revenue through the destocking cycle. FY2021→FY2025 (projection) ≈ 21%.
Commentary.
FY2022: Revenue rose 76%, driven by a full year of Tennants plus volume growth and higher realisations. Margin fell from 14.7% to 10.4% on raw-material and energy inflation and the lower-margin UK mix.
FY2023: Revenue grew 6%, almost entirely on price. Volumes were weak as the value chain had over-stocked during the oil spike. UK operations suffered from high energy costs. Margin held at 10.2%.
Q1 FY2024: Margin fell to about 8% as the UK business was hit by Chinese dumping of specialty chemicals.
FY2024: Revenue fell about 6% to ₹1,911 crore as crude-linked raw-material prices fell and passed through to realisations, while global F&F houses destocked amid US and European slowdowns. Margin nevertheless rebounded to 13.2% on cheaper inputs, and PAT rose to ₹94 crore. Indian volumes grew 14%.
H1 FY2025: Revenue grew about 13% with ~14% margins.
FY2025: The acquisition of SPC was expected to lift reported revenue to ~₹2,300 crore.
Data conflicts (FY2025–FY2026):
-
Tracxn's MCA-derived table shows irregular revenue numbers (5896, 5893, 7422, 3363, 3853) with no unit stated. These are irreconcilable with CRISIL and are disregarded.
-
Tofler lists standalone FY2026 operating revenue in a ₹1,500–1,750 crore band, with total revenue up 5.61% and EBITDA up 3.69%. This is consistent with a standalone (India-only) figure and is not comparable with the consolidated series above.
-
TheCompanyCheck reports a 3.09% revenue drop and 16.99% profit rise for "FY2024". This direction matches CRISIL; the magnitude differs, plausibly standalone vs consolidated.
Balance sheet
Notes:
-
FY2025 values are CRISIL projections made in Dec-2024 to capture acquisition debt; they are not reported actuals.
-
Net worth ₹813 crore is CRISIL's "adjusted networth" (Dec-2024 rationale, reflecting the Mar-2024 balance sheet).
-
An FY2023 net worth of ~₹707 crore is implied by 431 / 0.61 (derived; not shown in the table because CRISIL's gearing definition is "adjusted").
-
Not publicly disclosed: goodwill and intangibles, working capital in absolute terms, short- vs long-term debt split.
Debt composition evidence. Rated bank lines total ₹765 crore: working-capital facilities of ₹717.5 crore (Citibank ₹180 crore, Standard Chartered ₹160 crore, JP Morgan ₹125 crore, HDFC Bank ₹100 crore, DBS ₹77.5 crore, HSBC ₹75 crore) plus a Citibank standby letter of credit of ₹47.5 crore (CRISIL, Dec-2024). Earlier term debt (rupee term loans, FCTL and ECB from HDFC, Citi and HSBC) had largely amortised by Jan–Mar 2024 (CRISIL Oct-2023). The Sharon PC acquisition debt sits outside these rated lines; its quantum is not publicly disclosed. CRISIL expects it to have a long maturity.
Commentary.
Peak gearing (Mar-2021): 1.4–1.5x, after the debt-funded Tennants purchase.
Deleveraging (FY2022): Promoter equity infusion and accruals allowed ₹220 crore of prepayment, reducing gearing to 0.7x by FY2022 and 0.38x by FY2024.
Re-leveraging (FY2025): The Sharon PC deal re-levers the balance sheet. CRISIL projected debt/EBITDA of 4.72x at Mar-2025. It expected promoter equity to fund prepayment of 40–50% of the acquisition debt by November 2025, bringing debt/EBITDA to ~2.5–2.7x by end-FY2026.
Equity infusion status: Whether that infusion occurred is not publicly confirmed. PitchBook records a US$47.3 million "later stage" equity deal dated 14-May-2025 with one investor. That is consistent in timing and size (~₹400 crore) with a promoter infusion but is unconfirmed by the company. CRISIL's Nov-2025 reference to Eternis as still "Crisil A+/Stable" implies no rating stress.
Cash flow
Notes: Accrual figures are CRISIL forward-looking ranges (₹140–150 crore in Oct-2023; ₹200–250 crore in Dec-2024) shown at midpoint against the year of the rationale. Utilisation is 56% (FY2022), 69% (15 months to Jul-2023), and 54% (12 months to Sep-2024). Not publicly disclosed: operating cash flow, reported capex, free cash flow, dividends paid, buybacks. CRISIL notes promoters have extended timely liquidity support when needed.
Ratios
Notes: ROE FY2023 = 70 / ~707 (derived); FY2024 = 94 / 813. Debt/equity FY2025 is a CRISIL projection. Working-capital days are from CRISIL (Mar-2022 and Mar-2024). Not publicly disclosed: ROA, ROIC, current ratio, asset turnover.
Ratio commentary. Returns are modest. A ~10–12% ROE on a ~₹800 crore equity base, and PAT margins under 5%, show that Eternis has scale without specialty-grade pricing power. That is the core analytical issue for the business. Working capital is heavy, at roughly 160 days of receivables plus inventory, typical of an exporter serving multinational F&F houses on extended terms. Credit metrics in FY2024 were the strongest in the five-year window, which supported the A+ rating and gave headroom for the Sharon PC deal.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Role | Source |
|---|---|---|---|
Eternis Fine Chemicals Ltd (India) | Parent | Indian manufacturing (Kurkumbh, Koregaon-Bhima, Sinnar, new greenfield site), R&D, HQ | CRISIL |
Eternis Chemicals Pvt Ltd | Former 100% subsidiary; amalgamated into parent (order filed with ROC 21-Mar-2025) | Greenfield plant near Pune | CRISIL Nov-2025 |
AIMS Impex Pvt Ltd | Former subsidiary; merged into parent effective June 2018 | Coumarin, Sinnar (Nashik) | CRISIL |
Eternis UK Ltd | 100% subsidiary | UK holding and export marketing arm; acquisition vehicle for Sharon PC | CRISIL Dec-2024; CARE 2022 |
Eternis Fine Chemicals UK Ltd (ex-Tennants Fine Chemicals) | Step-down 100% subsidiary via Eternis UK Ltd | Leek manufacturing (aromas and acetate esters) | CRISIL |
Singapore and China subsidiaries (ex-Tennants) | Step-down subsidiaries | Regional distribution / service hubs | P&F+ 2021 |
Eternis Personal Care (ex-Sharon Personal Care), including Sharon Personal Care Srl (Trezzo sull'Adda, Italy) | Acquired 100% Dec-2024 via Eternis UK Ltd | Personal-care ingredients | CRISIL; eternis.com |
Eternis Fine Chemical USA LLC | Affiliate / importer of record (named as consignee on US import records) | US distribution hub | ImportInfo (bills of lading) |
SO.F.I.A Cosmétiques JV | Joint venture (stake undisclosed) | Cosmetic formulation and manufacturing, France | SOFW / P&F+ |
Business Units
| Business unit (management view) | Contents | Segment revenue | Segment profit / margin | Share of total |
|---|---|---|---|---|
Eternis Aroma Chemicals: India | Coumarin, salicylates, hydrogenation products (PTBCHA/OTBCHA/PTBCH), cyclamen aldehyde, HCA, Hamber, PEA, styrallyl acetate | — | — | — |
Eternis Aroma Chemicals: UK (Leek) | Aroma chemicals (e.g., benzyl benzoate, benzyl salicylate) and acetate esters; ~24,000–26,000 t/yr | Not publicly disclosed post-acquisition. At acquisition (2021), Tennants had ~US$85m / ~£62m annual sales. | Lower than India per CRISIL; hit by energy costs (FY2023) and Chinese dumping (Q1 FY2024) | — |
Eternis Personal Care | Preservatives, multifunctionals, actives, textures, wet-wipe and sun-care solutions; Italy plant; Israel microbiology lab; US, DE, FR distribution | — | — | CRISIL projected that consolidated FY2025 revenue including SPC would reach ~₹2,300 crore vs ₹1,911 crore in FY2024 |
“—” = not publicly disclosed.
Operating Metrics (tonnes) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Group aroma capacity (tonnes per annum) | 66,000 | 66,000 | 66,000 | 65,000 | 75,365 |
Total group production volume (tonnes) | — | — | 50,854 | 51,209 | — |
UK site annual output claimed (tonnes) | 24,000 | 24,000 | — | — | — |
Exports as % of consolidated turnover (%) | — | 75 | 75 | 75 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating income, consolidated (INR Cr) | 1,079 | 1,902 | 2,023 | 1,911 | 2,300 |
Revenue growth YoY (%) | — | 76 | 6 | -6 | 20 |
Operating (EBITDA-basis) margin (%) | 14.7 | 10.4 | 10.2 | 13.2 | — |
EBITDA, derived = income × margin (INR Cr) | 159 | 197 | 206 | 252 | — |
Profit after tax (INR Cr) | 38 | 70 | 70 | 94 | — |
PAT margin (%) | 3.5 | 3.7 | 3.4 | 4.9 | — |
Interest coverage (times) | 6.03 | 5.13 | 4.14 | 7.02 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Ratios (x) and Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Adjusted debt / adjusted net worth (times) | 1.39 | 0.70 | 0.61 | 0.38 | 1.67 |
Total debt / EBITDA (times) | — | — | 2.09 | 1.21 | 4.72 |
Total debt, derived = debt/EBITDA × EBITDA (INR Cr) | — | — | 431 | 305 | — |
Adjusted net worth (INR Cr) | — | — | — | 813 | — |
Cash and marketable securities (INR Cr) | — | — | — | 145 | — |
Net debt, derived (INR Cr) | — | — | — | 160 | — |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Net cash accruals, CRISIL estimate range midpoint (INR Cr) | — | 145 | 225 |
Planned annual capex, CRISIL expectation (INR Cr) | 80 | 50 | 50 |
Debt repaid / prepaid (INR Cr) | 220 | — | — |
Average bank-limit utilisation (%) | 56 | 69 | 54 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, derived = PAT / year-end adjusted net worth (%) | — | — | 9.9 | 11.6 | — |
Interest coverage (times) | 6.03 | 5.13 | 4.14 | 7.02 | — |
Debt / equity (times) | 1.39 | 0.70 | 0.61 | 0.38 | 1.67 |
Net debt / EBITDA, derived (times) | — | — | — | 0.63 | — |
Receivable days | — | 90 | — | 85 | — |
Inventory days | — | 81 | — | 70 | — |
Payable days | — | 83 | — | — | — |
Cash conversion cycle, derived (days) | — | 88 | — | — | — |
Revenue by Region (%)
| Region | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Exports, % of consolidated turnover (%) | 75 | 75 | 75 |
Domestic India, % of consolidated turnover (%) | 25 | 25 | 25 |
Region Overview
| Region | Evidence of activity | Trend signal |
|---|---|---|
North America | Eternis Fine Chemical USA LLC importer; 2,608 US bills of lading Mar-2019 to Jul-2025, with consignees including Givaudan Fragrances Corp. and Mane USA; Sharon PC US warehouse (Parsippany, NJ) and application lab | Growing: Sharon PC's 2023 US expansion plus Eternis US hub |
Europe | Leek (UK) manufacturing; Netherlands hub; sales teams in the Netherlands, Spain and France; Italy plant; Germany and France distribution (SPC); SO.F.I.A JV (France) | Mixed: UK margins pressured by energy costs and Chinese dumping (FY2023–24); personal care adds scale |
India | 4 plants; domestic F&F customers; volumes +14% in FY2024 | Strong per CRISIL Dec-2024 |
Asia-Pacific ex-India | Singapore hub; China subsidiary (ex-Tennants) | Personal care to be pushed into APAC via Eternis' network (Sharon PC CEO, Dec-2024) |
Middle East | Israel microbiology / innovation lab (Sharon heritage) | Israel no longer named as a manufacturing location in the Jul-2026 rebrand release; status unclear |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable: unlisted |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable. No traded equity; acquisition prices undisclosed. Listed peer Privi traded at ~₹2,352 per share around mid-2025 (Nuvama), with a market cap of ~₹6,669 crore at Mar-2025 (Blinkx), giving a reference for sector multiples. |
Analyst consensus | None (no coverage) |
Buybacks | None disclosed |
Equity issuance | Promoter infusion FY2022 (amount used for ₹220 crore prepayment); possible US$47.3m equity, May-2025 (PitchBook; unconfirmed) |
Moody's / S&P / Fitch | Not rated |
Domestic ratings | CRISIL A+/Stable (long-term), CRISIL A1 (short-term); CARE ratings withdrawn Mar-2022 |
Debt maturity profile | Rated lines are mainly short-term working capital (₹717.5 crore); legacy term loans matured Jan–Mar 2024; acquisition debt expected to have long maturity (CRISIL); details not publicly disclosed |
Capital Markets Data
| Metric | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
CRISIL long-term rating notch (A-=1, A=2, A+=3) | 1 | 2 | 2 | 2 | 3 | 3 |
Total rated bank facilities (INR Cr) | 345.84 | — | 651.4 | 765 | 765 | 765 |
Analyst Conclusions
Management guidance
No public financial guidance exists. Proxy expectations from CRISIL (Dec-2024):
-
Consolidated revenue of ~₹2,300 crore in FY2025 including Sharon PC.
-
Operating margin of about 13% over the medium term.
-
Annual cash accruals of ₹200–250 crore.
-
Debt/EBITDA falling to 2.5–2.7x by end-FY2026, contingent on promoter equity.
Consensus
None. The company has no analyst coverage.
Bull case
-
Margin re-rating via mix. FY2024 showed 13.2% operating margin even on falling revenue. Adding higher-value personal-care ingredients, lower-PCF premium variants and food-grade products could push margins into CRISIL's 14–16% upgrade band. That would roughly double PAT margin from sub-5%.
-
Structural China+1 and ESG pull. EcoVadis Gold/Silver, first-Indian TfS membership, and LCAs across most of the portfolio align Eternis with the Scope 3 agendas of Givaudan, dsm-firmenich, IFF and Symrise. The multi-country footprint (India, UK, Italy) is a supply-security asset few independents can match.
-
Professionalised platform with patient capital. The board and executive team now include an ex-DSM Personal Care & Aroma CEO and an ex-Symrise global president, alongside new global HR and procurement heads. Together with a 94%-owning promoter with a record of injecting equity, this supports further M&A and capacity growth without equity-market constraints.
Bear case
-
Commodity economics persist. Organic revenue was flat from FY2022 to FY2024. Margins swing with phenol and crude, and Chinese competition caps pricing. A ~10–12% ROE suggests the business barely earns its cost of capital.
-
Acquisition leverage and integration opacity. The Sharon PC price and returns are undisclosed. Leverage was projected at 4.7x debt/EBITDA, and completion of the promised promoter infusion is publicly unconfirmed. Personal-care preservatives is a crowded field dominated by larger specialists.
-
Customer and product concentration. Four buyers dominate demand and can integrate backward, as the ended Hedione® alliance illustrates. Two chemistries (hydrogenation and salicylates) still carry about a third of revenue.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Next CRISIL surveillance rationale (FY2025/FY2026 actuals) | First public read on post-acquisition leverage, margins and revenue |
| Confirmation of promoter equity infusion / acquisition-debt prepayment | Key rating sensitivity |
| FY2026 consolidated filing with MCA (AOC-4) | Segment and personal-care contribution |
| Eternis Personal Care growth in APAC / India | Validates the cross-selling thesis |
| SO.F.I.A JV first commercial wins | Downstream strategy proof-point |
| Leek UK profitability (energy, China competition) | Largest drag historically |
| ChainCraft / low-carbon product commercialisation | ESG premium monetisation |
| Any further debt-funded M&A | Explicit CRISIL downgrade trigger |
| Scope 1+2 trajectory vs. the 2030 target | Credibility of the ESG positioning |
Analyst verdict
Eternis Fine Chemicals is a credible, well-capitalised but structurally low-return aroma-chemicals manufacturer in the middle of a strategic transition. Over six decades the Mariwala family has built it from an oleochemicals and polyamides heritage into a scale supplier of commodity-to-semi-specialty fragrance molecules. It reaches every major F&F house, runs about 75,000 tonnes a year of capacity across India and the UK, and holds ESG credentials that lead its Indian peer group.
The financial record tempers that franchise value. Revenue grew at about 21% a year from FY2021 to FY2024, but almost entirely through the Tennants acquisition; organic revenue was flat from FY2022 to FY2024. Operating margins of 10–15% and PAT margins under 5% trail Privi Speciality, whose 22–26% EBITDA margins show what product focus and cost leadership can achieve in the same market. Eternis's A+ credit rating reflects balance-sheet conservatism and promoter backing more than earnings power.
The 2024–2026 programme is the right response. It brings a seasoned DSM/IGM chief executive, a personal-care second leg via Sharon (now fully rebranded), a downstream JV in France, and decarbonised products as a commercial lever. Whether these lift returns is still unproven in public data.
The binding constraint for any outside stakeholder is disclosure. With no public annual report, the two most important questions remain unanswered: whether the promised promoter equity was injected, and what Eternis Personal Care contributes. Until those are confirmed, Eternis should be viewed as a stable, investment-grade-equivalent counterparty (CRISIL A+) with moderate execution risk in its diversification. Its operating profile is improving but not yet differentiated. For suppliers and customers it is a dependable partner. For potential investors or acquirers, valuation would hinge on proof that margins can move sustainably above 14%.
Principal sources consulted
-
CRISIL Ratings rationales: 7-Jun-2018; 6-Oct-2021; 6-Jul-2022; 4-Oct-2023 (EFCL and ECPL); 13-Dec-2024 (EFCL and ECPL); 13-Nov-2025 (ECPL withdrawal)
-
CARE Ratings press release on Eternis Fine Chemicals, 22-Mar-2022
-
Eternis Fine Chemicals Sustainability Report 2023-24 (eternis.com PDF); eternis.com (Our Story, Products, News); eternis.co.uk
-
Newsfile / Yahoo Finance release, 4-Dec-2024 (Sharon PC acquisition); Global Cosmetics News; Personal Care Insights; GCI Magazine; Happi; AlchemPro
-
Personal Care Magazine, Cosmetics Business and HPC Mag MEA (Jul-2026 rebrand); Cosmetics Business (Trezzo plant); SpecialChem product listings
-
Perfumer & Flavorist+ (CEO interview 2024; Tennants 2021; SO.F.I.A; company page); SOFW; Euro Cosmetics Magazine
-
World Bio Market Insights (ChainCraft, Mar-2025); PITCCH case study; CERE
-
C&EN (Feb-2021); Invest Staffordshire; Lawyer Monthly; Avendus; Outlook Business; CB Insights; Owler
-
MCA-derived aggregators: Zauba Corp, Tofler, Tracxn, TheCompanyCheck; Bloomberg, PitchBook, Crunchbase, ZoomInfo, RocketReach, LeadIQ profiles
-
LinkedIn company posts; Indian Chemical News; HR Today (Apr-2026, Jul-2026); ImportInfo US customs records
-
Peer data: Nuvama Q4FY25 chemicals review; Whalesbook and ScanX (Privi FY2026); Simply Wall St (Oriental Aromatics FY2025); Blinkx; Wikipedia (Together for Sustainability member list)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Source |
|---|---|---|---|---|
Rajendra (Rajen) K. Mariwala | Promoter & Managing Director | MD since 1-Apr-1995 | Mariwala family; President of the Indian Chemical Council (per Sustainability Report) | TheCompanyCheck; Sustainability Report |
Wilfrid Gambade | Group CEO (France-based) | Since Apr-2024 | CEO IGM Resins (2021–24, PE-owned); DSM: President Protective Materials (2018–21), President Personal Care & Aroma Ingredients (2014–17), President Composites & Synres (2011–14); earlier Huntsman, Ciba Specialty Chemicals (EU, US), Allied Colloids | Indian Chemical News; ContactOut; P&F+ |
Chetan D. Chowatia | Chief Financial Officer (KMP) | Since 25-May-2023 | — | TheCompanyCheck |
Shailendra Arora | Whole-time Director | Since 25-Jun-2025 | — | TheCompanyCheck |
Krishan K. Sharma | Whole-time Director (per SR 2023-24) | — | — | Sustainability Report; Zauba |
Billy Gittins | VP Strategy, Marketing & Product Management | Since 2021 (ex-MD Tennants Fine Chemicals) | Board member, UK Chemical Industries Association | P&F+; Sustainability Report |
David Whitaker | VP New Product Development & Product Management | — | Chair, IFRA UK | Sustainability Report |
Hari Menon | Global Chief Human Resources Officer | Since Jun-2025 | Previously Mitsui O.S.K. Lines | People Matters via ZoomInfo/LeadIQ |
Robert Monti | President, Eternis Personal Care | From 2026 rebrand | — | Personal Care Magazine |
Naama Eylon | Former CEO/President, Sharon Personal Care | Through integration (2024–25) | Sharon PC | Happi; AlchemPro |
Shagufta Nahid | Head of Procurement – Global (Aroma & Personal Care) | Since Apr-2026 | Unilever (Senior Procurement Manager, Personal Care South Asia); PepsiCo, IKEA, BP, DuPont | HR Today |
Mahesh Dicholkar | Head of HR – Manufacturing | Since Jul-2026 | — | HR Today |
Simon Cull | Sustainability contact (UK) | — | — | Sustainability Report |
“—” = not publicly disclosed.
Board of Directors
| Director | Category (per SR 2023-24) | Notes |
|---|---|---|
Harsh C. Mariwala | Non-executive | Mariwala family; founder-chairman of Marico (widely reported) |
Dr. Ravindra K. Mariwala | Non-executive | Director since 5-Apr-2000 (MCA) |
Rajendra K. Mariwala | Managing Director | — |
Krishan Sharma | Whole-time Director | — |
Arun Bewoor | Independent | — |
Anita Belani | Independent | Director since 5-May-2015 |
Ketan Dalal | Independent | Director since 9-Aug-2021 |
Milind Sarwate | Independent | — |
Governance Overview
| Governance metric | Value | Source |
|---|---|---|
Board size (FY2024) | 8 | Sustainability Report |
Independent directors (FY2024) | 4 of 8 (50%) | Sustainability Report |
Women on board | 12.5% (1 of 8) | Sustainability Report |
Board meetings FY2024 | 6 | Sustainability Report |
Committees | Audit; Nomination & Remuneration; CSR; plus a Risk Management Committee reporting to the Board | Sustainability Report |
Chair / CEO separation | MD (promoter) and Group CEO (professional) are separate roles. Board chair identity not disclosed. | — |
Whistleblower incidents FY2024 | 0 | Sustainability Report |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Promoter / Mariwala family group | 94.38% (2023) | TheCompanyCheck (MCA) |
Public / other | 5.62% (2023) | TheCompanyCheck |
Institutional holders (top 10) | Not applicable / not publicly disclosed. No listed float. | — |
PitchBook-recorded equity deal | US$47.3m, 14-May-2025, 1 investor (identity not disclosed). Unconfirmed; possibly the promoter infusion anticipated by CRISIL. | PitchBook |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Positioning vs. Eternis |
|---|---|---|---|
Aroma chemicals (India) | Privi Speciality Chemicals (listed) | Direct; India's largest aroma exporter by its own claim | Larger and far more profitable (FY2026 revenue ₹2,583 crore, EBITDA margin 25.8%); pine-chemistry led |
Aroma chemicals (India) | Oriental Aromatics (listed) | Direct | Smaller (FY2025 revenue ₹928 crore, EBITDA margin ~10%); camphor and terpene focus |
Aroma chemicals (India) | Hindustan Mint & Agro, Keva / S H Kelkar (listed) | Partial overlap | Owler lists both as competitors; SHK is primarily a fragrance compounder |
Aroma chemicals (global, captive) | Givaudan | Customer-competitor | Backward-integrated in some molecules |
Aroma chemicals (global, captive) | dsm-firmenich | Customer-competitor | Makes Hedione® and other captives |
Aroma chemicals (global, captive) | Symrise | Customer-competitor | Large integrated aroma-molecule producer |
Aroma chemicals (global, captive) | IFF | Customer-competitor | Captive ingredients |
Aroma chemicals (global, merchant) | BASF (Aroma Ingredients) | Direct | Petrochemical-integrated merchant producer of citral-based molecules |
Aroma chemicals (global, merchant) | Takasago, Kao (Japan) | Direct / partial | Specialty aroma molecules |
Aroma chemicals (global, merchant) | Chinese producers (various) | Direct | Price-setters in commodity molecules; dumping cited by CRISIL as a UK headwind in FY2024 |
Personal-care preservatives / functionals | Symrise Cosmetic Ingredients, Lonza/Arxada, Schülke & Mayr, Ashland, Clariant, Lanxess (named as category participants; no figures compiled) | Direct | Larger, global players with broader portfolios |
Peer Comparison FY2025
| Metric | Eternis (FY2024, consolidated) | Privi Speciality (FY2025, consolidated) | Oriental Aromatics (FY2025) |
|---|---|---|---|
Revenue | 1,911 | 2,101 | 928 |
Revenue growth YoY (%) | -6 | 20 | 10 |
EBITDA | 252 (derived) | 454 | 93 |
EBITDA margin (%) | 13.2 | 22 | 10 |
PAT | 94 | 185 | 34 |
PAT margin (%) | 4.9 | 8.8 | 3.7 |
R&D intensity (%) | — | Not compiled | Not compiled |
“—” = not publicly disclosed.
Recent Developments
The window is approximately April 2025 to October 2026; three late-2024 items are included for context.
Not identified in public sources: * guidance revisions, litigation, regulatory penalties, layoffs or plant incidents in the window.



